Odyssey Marine Exploration Inc. Stock
We can see a decrease in the price for Odyssey Marine Exploration Inc.. Compared to yesterday it has lost -€0.011 (-2.170%).
So far the community has only identified positive things for Odyssey Marine Exploration Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Odyssey Marine Exploration Inc. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Odyssey Marine Exploration Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Odyssey Marine Exploration Inc. | -2.170% | -14.815% | -28.329% | -55.221% | -70.751% | -84.850% | -89.048% |
| Endava plc ADR ADR | 1.930% | 5.957% | -10.432% | -76.058% | -55.536% | -94.791% | - |
| Aikido Pharma Inc. | -1.590% | -6.392% | -20.105% | -43.737% | -42.834% | -21.397% | -82.161% |
| Lightbridge Corp. | 2.240% | 8.301% | -8.754% | -36.837% | -37.060% | 21.186% | 36.190% |
Comments
Odyssey Marine Exploration, Inc. (NASDAQ: OMEX) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for OMEX provided by MarketBeat
Odyssey Marine Exploration, Inc. (NASDAQ: OMEX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for OMEX provided by MarketBeat
Odyssey Marine Exploration, Inc. (NASDAQ: OMEX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for OMEX provided by MarketBeat
News
Agnico Eagle Mines Eyes 20%-30% Gold Production Growth Through Organic Expansion
Key Points
- Interested in Agnico Eagle Mines Limited? Here are five stocks we like better.
- Agnico Eagle expects to increase annual gold production by 20%–30% over the next five to 10 years
Movie Theater Stocks Are So Hot That Even AMC Is Crushing the Market
If you're one of those perpetual bashers of multiplex operators, don't sleep on a plot twist of M. Night Shyamalan proportions. Exhibitors worldwide are doing something they haven't done since 2019
OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near
Key Points
- Interested in OnKure Therapeutics, Inc.? Here are five stocks we like better.
- OnKure Therapeutics is advancing two lead allosteric PI3Kα inhibitors, OKI-355 for vascular anomalies